Diosmectite — the active pharmaceutical ingredient in the branded generic drug Biqi, which is manufactured by Nanjing China-based Simcere Pharmaceutical Group — has passed EU-GMP inspection, enabling Simcere to market diosmectite in the European Union.
Simcere has been manufacturing and marketing diosmectite API and formulations under the Biqi brand name for many years in China. Diosmectite is made from a natural mineral material and its formulation is the leading antidiarrheal drug in China and France. Simcere owns a high grade diosmectite mine in China.
Jinsheng Ren, the chairman and CEO of Simcere Pharmaceutical Group commented that this was an important start in driving the group's international business.